SanDisk, Moderna, Twist Lead Large-Cap Momentum Stocks, But Fundamentals Diverge

SanDisk (SNDK), Moderna (MRNA), and Twist Bioscience (TWST) have posted the highest year-to-date returns among U.S. large-cap stocks, but their underlying financial health tells starkly different stories. While all three exhibit powerful price momentum, only SanDisk's rally is currently supported by strong profitability and revenue growth, according to an analysis by Investing.com.

Top Performers by the Numbers

A screen of 498 U.S. large-cap companies, ranked by year-to-date (YTD) price performance, identified these three as the market leaders. Their key financial metrics highlight a clear divergence in operational performance.

• SanDisk (SNDK): Has seen its stock climb 628.7% YTD, backed by revenue growth of 175.3% and a return on invested capital (ROIC) of 79.7%.
• Moderna (MRNA): The stock has surged 589.9% YTD, despite negative revenue growth of -27.6% and a negative ROIC of -22.8%.
• Twist Bioscience (TWST): Shows a YTD return of 486.8% with positive revenue growth of 19.2%, but it remains unprofitable with a negative P/E ratio and an ROIC of -20.8%.

Fundamentals vs. Speculative Rallies

Ad

The data reveals two distinct types of momentum. SanDisk represents a rally underpinned by robust fundamentals, where exceptional earnings power and sales growth appear to justify the stock's appreciation. Its positive P/E ratio of 23.6x further distinguishes it from the others.

In contrast, the rallies in Moderna and Twist Bioscience appear more speculative. According to the analysis, Moderna's share price performance suggests the market is pricing in a significant operational recovery that has not yet materialized in its financial statements. Similarly, while Twist Bioscience is growing its sales, its substantial losses indicate that price momentum is the primary driver of its stock performance, not current profitability.

Context for Investors

This analysis underscores the importance of looking beyond price momentum to assess the quality of an asset's performance. The source report notes that while all three companies lead in momentum, a clear split exists between SanDisk's proven earnings power and the operational improvements required at Moderna and Twist Bioscience to justify their respective valuations.